World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
13230
World Ranking
3862
National Ranking
28

Gal Markel publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Gal Markel sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 179 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Gal Markel D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Gal Markel sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Gal Markel is affiliated with Tel Aviv University in Israel and has a research focus primarily in medicine and biochemistry, genetics, and molecular biology. Their work spans several subfields including oncology, molecular biology, immunology, pulmonary and respiratory medicine, and statistics and probability.

The scientist's research topics include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Health Systems, Economic Evaluations, Quality of Life
  • Melanoma and MAPK Pathways
  • Immune Cell Function and Interaction
  • Statistical Methods in Clinical Trials

Gal Markel has contributed to numerous publications, with a strong presence in well-known scientific journals and venues. Their frequent publication venues include:

  • The Lancet Oncology
  • Cancers
  • JAMA Network Open
  • Journal for ImmunoTherapy of Cancer
  • Bioinformatics

Some recent scientific papers by Gal Markel are:

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients, 2020, Science
  • MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma, 2020, OncoImmunology
  • Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma, 2020, Cancers
  • Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma, 2022, JAMA Network Open
  • Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy, 2021, Journal for ImmunoTherapy of Cancer

Gal Markel has collaborated extensively with several co-authors, reflecting a network of frequent scientific partnerships. These frequent co-authors include:

  • Tomer Meirson
  • David Bomze
  • Nethanel Asher
  • Jacob Schachter
  • Ronnie Shapira-Frommer

Best Publications

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    Erez N. Baruch;Erez N. Baruch;Ilan Youngster;Guy Ben-Betzalel;Rona Ortenberg

  • Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

    Chamutal Gur;Yara Ibrahim;Batya Isaacson;Rachel Yamin

  • Characterization of the expression of MHC proteins in human embryonic stem cells

    Micha Drukker;Gil Katz;Achia Urbach;Maya Schuldiner

  • Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

    Tal I Arnon;Hagit Achdout;Ofer Levi;Gal Markel

  • Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    Michal J. Besser;Ronnie Shapira-Frommer;Orit Itzhaki;Avraham J. Treves

  • CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells.

    Jacob Hanna;Ori Wald;Debra Goldman-Wohl;Diana Prus

  • Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    Michal Harel;Rona Ortenberg;Rona Ortenberg;Siva Karthik Varanasi;Kailash Chandra Mangalhara

  • Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis

    Einav Shoshan;Aaron K. Mobley;Russell R. Braeuer;Takafumi Kamiya

  • Tumor and viral recognition by natural killer cells receptors.

    Tal I. Arnon;Gal Markel;Ofer Mandelboim

  • CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

    Gal Markel;Niva Lieberman;Gil Katz;Tal I. Arnon

  • Establishment and large-scale expansion of minimally cultured young tumor infiltrating lymphocytes for adoptive transfer therapy

    Orit Itzhaki;Einat Hovav;Yaara Ziporen;Daphna Levy

  • Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

    Hamzah Abu-Sbeih;David M. Faleck;Biagio Ricciuti;Biagio Ricciuti;Robin B. Mendelsohn

  • MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth

    Yael Nemlich;Eyal Greenberg;Eyal Greenberg;Rona Ortenberg;Rona Ortenberg;Michal J. Besser

  • Complexes of HLA-G Protein on the Cell Surface Are Important for Leukocyte Ig-Like Receptor-1 Function

    Tsufit Gonen-Gross;Hagit Achdout;Roi Gazit;Jacob Hanna

  • Triage and management of pericardial effusion.

    Massimo Imazio;Bongani M Mayosi;Antonio Brucato;Gal Markel

  • Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

    Merav Lidar;Merav Lidar;Eitan Giat;Daniela Garelick;Yuval Horowitz

  • Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

    Ricardo A. de Azevedo;Ricardo A. de Azevedo;Einav Shoshan;Shanzhi Whang;Gal Markel

  • Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions

    Gal Markel;Dana Wolf;Jacob Hanna;Roi Gazit

  • Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.

    Noam Stern;Gal Markel;Tal I. Arnon;Raizy Gruda

Frequent Co-Authors

Jacob Schachter
Jacob Schachter Sheba Medical Center
Ofer Mandelboim
Ofer Mandelboim Hebrew University of Jerusalem
Iris Barshack
Iris Barshack Sheba Medical Center
Jacob H. Hanna
Jacob H. Hanna Weizmann Institute of Science
Richard S. Blumberg
Richard S. Blumberg Brigham and Women's Hospital
Arnon Nagler
Arnon Nagler Sheba Medical Center
Angel Porgador
Angel Porgador Ben-Gurion University of the Negev
Gideon Rechavi
Gideon Rechavi Sheba Medical Center
Dana G. Wolf
Dana G. Wolf Hebrew University of Jerusalem
Omry Koren
Omry Koren Bar-Ilan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare careers often require foundational nursing education. Many students explore options like accelerated RN to NP programs to fast-track their progression into advanced nursing roles that intersect with immunological sciences.

If you’re starting fresh without a nursing background, consider 12-month accelerated nursing programs online for non nurses. These intensive programs equip students with essential nursing skills in a condensed timeframe, making a nursing career more accessible while supporting future specialization.

For undergraduate students aiming to enter nursing quickly, the easiest ABSN programs to get into offer a streamlined path to earning a Bachelor of Science in Nursing. These programs balance accessibility with quality education, an excellent step before advancing to immunology-focused roles.

Additionally, for those seeking entry-level nursing positions, easy LPN programs to get into provide practical training and quick certification. This can serve as a stepping stone to more specialized healthcare careers connected to immunology.

Best Scientists Citing Gal Markel

Trending Scientists

Recently Published Articles